

The Biomarkers ESIG



Kostas Sechidis¹, Guillaume Desachy², Nicole Krämer³, Nils Tèrnes⁴ and Karl Köchert⁵, on behalf of the ESIG

¹Novartis AG ²Pierre Fabre Group ³Boehringer Ingelheim Pharma GmbH & Co KG ⁴Sanofi ⁵Bayer AG

We advance Precision Medicine.



We are on a mission to bring precision medicine to life.

We identify innovative approaches, discuss the latest research, and share best practices.


We use them to promote the use of biomarkers in clinical development

Use our collection of **publicly available biomarker datasets** to evaluate novel biomarker-based methods.



Watch our recent webinar “A promising **adaptive biomarker-based design** strategy for early phase and **machine learning as an enabler of precision medicine!**”

We enhance Biomarker Insights.



We provide practical solutions on topics related to biomarker modeling.


We develop and contribute to hands-on guidance, discuss the challenges that we face, and share experiences.

This enables the community to generate meaningful biomarker insights for the various stages of clinical development.



Our Machine Learning for Biomarkers workstream provided **feedback to regulatory guidance documents.**

We work on a ‘Kaggle’ initiative for **biology-informed predictive biomarker identification.**



We foster Collaborative Learning.



We build a collaborative and interactive learning community on biomarker topics.


We enable active discussions, knowledge sharing, and problem-solving – for the benefit of the wider community, not only for the Biomarkers ESIG members.

We offer regular meetings, workshops, case studies, and collaborative projects.



We organized special sessions at the PSI conferences 2023 & 2024, including a tutorial on **digital biomarkers.**

We organized a **Wonderful Wednesday Webinar** with the Data Visualization SIG on the analysis of microbiome data.



We are a diverse group of people from industry and academia. We share a strong interest in biomarkers, with a focus on clinical development.

Guillaume Desachy and Nicole Krämer co-lead our group. We have a dedicated AI/Machine Learning for Biomarkers workstream, which is co-led by Nils Tèrnes and Karl Köchert.